[Form 4] BeOne Medicines Ltd. Insider Trading Activity

Rhea-AI Filing Summary

BeOne Medicines Ltd. reporting person Lee Chan Henry (SVP, General Counsel) disclosed multiple transactions in American Depositary Shares (ADS) and options on 10/08/2025. The filing shows several sales under a Rule 10b5-1 plan adopted 05/14/2025, including weighted-average sale prices around $350 and $351. Offsetting purchases and transfers of ADS occurred the same day at prices between $159.03 and $213.32. After those transactions the reporting person holds 9,559 ADS equivalent and direct beneficial ownership in 223,106 ordinary shares. The report also discloses exercise/vesting schedules for outstanding options totaling 127,062 ordinary shares exercisable through 06/04/2034, with stated exercise prices shown in the filing.

Positive

• Sales executed under a Rule 10b5-1 plan adopted on 05/14/2025, which documents a prearranged trading program
• Reporting person retains material equity and option exposure: 223,106 ordinary shares and options covering 127,062 ordinary shares, indicating continued ownership stake

Negative

• Multiple sizable ADS sales on 10/08/2025 at weighted-average prices near $350, reducing immediate stake
• Outstanding options total potential dilution of at least 127,062 ordinary shares exercisable through 06/04/2034

Insights

Corporate Insider Trading Analyst

Insider executed multiple ADS sales under a 10b5-1 plan while retaining sizable option exposure.

The filing records contemporaneous sales and acquisitions of American Depositary Shares on 10/08/2025, with sales disclosed at weighted-average prices near $350 and $351. The reporter states the sales were effected under a Rule 10b5-1 plan adopted on 05/14/2025, which provides an affirmative defense for pre‑arranged trades.

Material dependencies include continued vesting of options through 06/04/2034 and the reporting person's residual equity: 223,106 ordinary shares beneficially owned and options covering 127,062 ordinary shares. Near-term items to watch are future scheduled vesting dates and any additional 10b5-1 plan transactions that would change listed holdings.

Equity Compensation Specialist

Significant option grants remain outstanding with multi-year vesting schedules and zero stated option price in the filing summary.

The report lists three option awards that, when converted, underlie 3,926, 116,493, and 3,848 ordinary shares respectively, with exercise prices disclosed (e.g., $14.96, $16.41, $12.23) and vesting schedules spanning four years from grant dates in 2023 and 2024.

These awards create future dilution potential as they vest and become exercisable through 08/04/2032, 06/14/2033, and 06/04/2034. Monitor net share count changes as options vest and any exercises are reported.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lee Chan Henry

(Last) (First) (Middle)

C/O BEONE MEDICINES I GMBH

AESCHENGRABEN 27, 21ST FLOOR

(Street)

BASEL V8 4051

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BeOne Medicines Ltd. [ ONC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
10/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares								223,106	D
American Depositary Shares(1)	10/08/2025		S(2)		1,112	D	$350	0	D
American Depositary Shares(1)	10/08/2025		M		302	A	$194.47	302	D
American Depositary Shares(1)	10/08/2025		M		8,961	A	$213.32	9,263	D
American Depositary Shares(1)	10/08/2025		M		296	A	$159.03	9,559	D
American Depositary Shares(1)	10/08/2025		S(2)		664	D	$347.82	8,895	D
American Depositary Shares(1)	10/08/2025		S(2)		4,733	D	$350.2177(3)	4,162	D
American Depositary Shares(1)	10/08/2025		S(2)		4,162	D	$351.1232(4)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	$14.96(5)	10/08/2025		M			3,926	(6)	08/04/2032	Ordinary Shares	3,926	$0	39,624	D
Share Option (Right to Buy)	$16.41(5)	10/08/2025		M			116,493	(7)	06/14/2033	Ordinary Shares	116,493	$0	109,109	D
Share Option (Right to Buy)	$12.23(5)	10/08/2025		M			3,848	(8)	06/04/2034	Ordinary Shares	3,848	$0	127,062	D

Explanation of Responses:

1. Each American Depositary Share represents 13 Ordinary Shares.

2. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2025.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $350.00 to $350.98, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $351.00 to $351.53, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

5. The number of securities underlying each option and the exercise price therefore are represented in ordinary shares.

6. These securities vest over a four-year period as follows: 25% on July 29, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

7. These securities vest over a four-year period as follows: 25% on the first anniversary of June 15, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

8. These securities vest over a four-year period as follows: 25% on the first anniversary of June 5, 2024 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

Remarks:

	/s/ Qing Nian, as Attorney-in-Fact	10/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did BEIGF insider Lee Chan Henry sell on 10/08/2025?

The filing shows multiple sales of American Depositary Shares (ADS) on 10/08/2025, executed under a Rule 10b5-1 plan, with weighted-average sale prices near $350 and $351.

How many ordinary shares does the reporting person beneficially own after these transactions?

The report shows the reporting person beneficially owns 223,106 ordinary shares following the reported transactions.

What option holdings and vesting schedules are disclosed for BEIGF insider?

Options disclosed convert to 3,926, 116,493, and 3,848 ordinary shares with vesting schedules over four years and exercisable through 08/04/2032, 06/14/2033, and 06/04/2034.

Were the ADS sales part of a prearranged trading plan?

Yes. The filing states the sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 05/14/2025.

What were the purchase prices for ADS bought on the same date?

Purchases on 10/08/2025 were reported at prices such as $159.03 and $213.32 for certain ADS transactions.